ipamorelin peptide cycle / CJC 1295 CJC-1295 + Ipamorelin: Timeline &

KA, kainite

Nakano, S.-i, Karimata, H

10.1128/aem.00357-22 111 GouletV.MarchettiP

Disclosures: Sai Santosh Babu Komakula: Nothing to Disclose, Xiaodong Ge: Nothing to Disclose, Wei Chen: Nothing to Disclose, Romain Desert: Nothing to Disclose, Hui Han: Nothing to Disclose, Zhuolun Song: Nothing to Disclose, Sukanta Das: Nothing to Disclose, Dipti Athavale: Nothing to Disclose, Nithyananthan Subramaniyam: Nothing to Disclose, Chao Wang: Nothing to Disclose, Dan Lantvit: Nothing to Disclose, Abid Anwar: Nothing to Disclose, Natalia Nieto: Nothing to Disclose 2637 PRIMARY GRAFT DYSFUNCTION AND MAJOR ADVERSE CARDIAC EVENTS AFTER HEPATITIS C VIREMIC HEART TRANSPLANTATION TO AVIREMIC RECIPIENTS Ritika Mazumder 1 Sarah Khan 1 Sakthi Surya Prakash 1 Qijun Yang 1 Omar Sims 1 Randall Starling 1 William Carey 1 , 1 Cleveland Clinic Foundation Background: Although direct-acting antiviral therapy (DAA) has enabled successful use of hepatitis C (HCV) positive allografts with favorable short-term outcomes, there is a notable absence of studies comprehensively examining cardiac events following HCV viremic heart transplantation

Treatment with ACEIs or ARBs reduces EGR1 expression in glomeruli, inhibits renin expression, decreases secretion of TNF-a and fibronectin proteins (FN) from tethered cells, slows tethered cell injury, and affects the behavior of MCs [75]